Compare · NTLA vs TKNO
NTLA vs TKNO
Side-by-side comparison of Intellia Therapeutics Inc. (NTLA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTLA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $1.40B, about 2.9x TKNO ($480.0M).
- Over the past year, NTLA is up 22.0% and TKNO is up 77.9% - TKNO leads by 55.9 points.
- NTLA has been more active in the news (18 items in the past 4 weeks vs 3 for TKNO).
- NTLA has more recent analyst coverage (25 ratings vs 10 for TKNO).
- Company
- Intellia Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- $10.06+5.34%
- $7.65-1.92%
- Market cap
- $1.40B
- $480.0M
- 1M return
- -10.09%
- +24.59%
- 1Y return
- +22.02%
- +77.91%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 10
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest NTLA
- SEC Form S-3ASR filed by Intellia Therapeutics Inc.
- Amendment: Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
- SEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.
- Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Intellia Therapeutics Inc.
- Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Latest TKNO
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Third Quarter 2026 Financial Results
- Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 8-K filed by Alpha Teknova Inc.
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Pricing of $40 Million Public Offering of Common Stock
- SEC Form 424B5 filed by Alpha Teknova Inc.
- Teknova Announces Proposed Public Offering of Common Stock
- Teknova Announces Preliminary Third Quarter Financial Results